Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$11.98 +4.3%	$9.84	$3.33 ▼ $12.43	$1.79B	1.83	1.63 million shs	1.02 million shs
CGEM Cullinan Therapeutics	$7.81 +0.6%	$8.10	$6.85 ▼ $21.01	$460.90M	-0.08	517,051 shs	146,725 shs
CNTA Centessa Pharmaceuticals	$14.34 +4.3%	$12.90	$8.46 ▼ $19.09	$1.88B	1.45	743,601 shs	689,124 shs
SPRY ARS Pharmaceuticals	$16.49 -1.6%	$14.85	$8.86 ▼ $18.90	$1.62B	0.9	1.34 million shs	881,491 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	0.00%	+1.58%	+20.00%	+60.32%	+253.27%
CGEM Cullinan Therapeutics	0.00%	+0.64%	-13.89%	+5.40%	-53.46%
CNTA Centessa Pharmaceuticals	0.00%	+9.18%	+14.41%	+22.73%	+67.07%
SPRY ARS Pharmaceuticals	0.00%	-9.42%	+19.28%	+28.79%	+81.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	3.346 of 5 stars	1.4	3.0	4.2	2.5	2.5	0.6
CGEM Cullinan Therapeutics	1.5334 of 5 stars	3.5	1.0	0.0	0.0	1.7	0.6
CNTA Centessa Pharmaceuticals	3.0454 of 5 stars	3.5	3.0	0.0	1.5	3.3	0.6
SPRY ARS Pharmaceuticals	3.2596 of 5 stars	3.6	1.0	0.0	3.2	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	-11.73% Downside
CGEM Cullinan Therapeutics	3.00	Buy	$30.00	284.12% Upside
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.89	94.55% Upside
SPRY ARS Pharmaceuticals	3.17	Buy	$31.00	88.05% Upside

Current Analyst Ratings Breakdown

Latest CGEM, ADPT, SPRY, and CNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/11/2025	CGEM Cullinan Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00
5/28/2025	CNTA Centessa Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
5/12/2025	CGEM Cullinan Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $24.00
5/8/2025	CNTA Centessa Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$6.00
5/8/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
5/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00 ➝ $13.00
5/5/2025	ADPT Adaptive Biotechnologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $9.00
5/2/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
4/16/2025	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	10.17	N/A	N/A	$1.37 per share	8.74
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$10.14 per share	N/A
CNTA Centessa Pharmaceuticals	$6.85M	279.48	N/A	N/A	$3.05 per share	4.70
SPRY ARS Pharmaceuticals	$89.15M	18.16	$0.01 per share	1,950.80	$2.64 per share	6.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	7/30/2025 (Estimated)
CGEM Cullinan Therapeutics	-$167.38M	-$2.91	N/A	N/A	N/A	N/A	-29.47%	-28.19%	8/6/2025 (Estimated)
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.81	N/A	N/A	N/A	N/A	-40.22%	-29.95%	8/12/2025 (Estimated)
SPRY ARS Pharmaceuticals	$8M	-$0.16	N/A	N/A	N/A	-16.11%	-6.94%	-5.60%	8/5/2025 (Estimated)

Latest CGEM, ADPT, SPRY, and CNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	SPRY ARS Pharmaceuticals	-$0.35	-$0.35	N/A	-$0.35	$7.48 million	$7.97 million
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.20	+$0.15	-$0.20	N/A	N/A
5/8/2025	Q1 2025	CGEM Cullinan Therapeutics	-$0.78	-$0.74	+$0.04	-$0.74	N/A	N/A
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
CGEM Cullinan Therapeutics	N/A	11.62	11.62
CNTA Centessa Pharmaceuticals	0.28	14.37	14.37
SPRY ARS Pharmaceuticals	0.30	11.00	10.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
CGEM Cullinan Therapeutics	86.31%
CNTA Centessa Pharmaceuticals	82.01%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
CGEM Cullinan Therapeutics	7.16%
CNTA Centessa Pharmaceuticals	7.09%
SPRY ARS Pharmaceuticals	33.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
CGEM Cullinan Therapeutics	30	59.01 million	54.79 million	Optionable
CNTA Centessa Pharmaceuticals	200	133.55 million	124.09 million	Optionable
SPRY ARS Pharmaceuticals	90	98.21 million	65.31 million	Optionable

CGEM, ADPT, SPRY, and CNTA Headlines

Recent News About These Companies

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells $254,850.00 in Stock

July 4 at 7:48 AM | insidertrades.com

Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 15,000 Shares of Stock

July 3 at 6:41 PM | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Major Shareholder James E. Flynn Sells 740,149 Shares

July 2 at 5:18 AM | insidertrades.com

James E. Flynn Sells 740,149 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

July 1, 2025 | marketbeat.com

Peregrine Capital Management LLC Boosts Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

July 1, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5% - Here's What Happened

June 30, 2025 | marketbeat.com

Lisanti Capital Growth LLC Buys New Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 29, 2025 | marketbeat.com

55,714 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Purchased by Matisse Capital

June 28, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded to "Hold" at Wall Street Zen

June 28, 2025 | americanbankingnews.com

ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded at Wall Street Zen

June 28, 2025 | marketbeat.com

ARS Pharmaceuticals (NASDAQ:SPRY) Sets New 12-Month High - Still a Buy?

June 27, 2025 | marketbeat.com

Leerink Partnrs Analysts Raise Earnings Estimates for SPRY

June 26, 2025 | americanbankingnews.com

Q2 EPS Estimate for ARS Pharmaceuticals Boosted by Analyst

June 25, 2025 | marketbeat.com

Harbour Capital Advisors LLC Purchases New Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 25, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Bought by AssuredPartners Investment Advisors LLC

June 25, 2025 | marketbeat.com

What is Leerink Partnrs' Estimate for SPRY FY2029 Earnings?

June 25, 2025 | americanbankingnews.com

Brokers Offer Predictions for SPRY FY2029 Earnings

June 24, 2025 | marketbeat.com

Janney Montgomery Scott LLC Boosts Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

June 23, 2025 | marketbeat.com

Eric Karas Sells 15,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

June 20, 2025 | marketbeat.com

249,230 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Acquired by Advisor Resource Council

June 20, 2025 | marketbeat.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Average Recommendation of "Buy" by Brokerages

June 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGEM, ADPT, SPRY, and CNTA Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$11.98 +0.50 (+4.32%)

Closing price 07/3/2025 03:56 PM Eastern

Extended Trading

$12.03 +0.05 (+0.45%)

As of 07/3/2025 04:47 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Cullinan Therapeutics NASDAQ:CGEM

$7.81 +0.05 (+0.64%)

Closing price 07/3/2025 01:00 PM Eastern

Extended Trading

$7.80 -0.01 (-0.19%)

As of 07/3/2025 04:20 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Centessa Pharmaceuticals NASDAQ:CNTA

$14.34 +0.60 (+4.33%)

As of 07/3/2025 02:56 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

ARS Pharmaceuticals NASDAQ:SPRY

$16.48 -0.27 (-1.58%)

Closing price 07/3/2025 03:38 PM Eastern

Extended Trading

$16.52 +0.04 (+0.21%)

As of 07/3/2025 04:43 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time